We compared the expression profiles of three CRC subclasses with a published dataset (25), which included a number of 47 melanoma patients that received programmed cell death protein-1 (PD-1) immune checkpoint inhibitor or cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) immune checkpoint inhibitor treatment. Here, CTLA4 is linked to melanoma.